Therapeutic prospect of Syk inhibitors
- 11 August 2009
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Therapeutic Patents
- Vol. 19 (10) , 1361-1376
Abstract
The non-receptor spleen tyrosine kinase (Syk; EC 2.7.10.2) is involved in signal transduction in a variety of cell types. In particular, it is a key mediator of immune receptors signaling in host inflammatory cells (B cells, mast cells, macrophages and neutrophils), important for both allergic and antibody-mediated autoimmune diseases. Deregulated Syk kinase activity also allows growth factor-independent proliferation and transforms bone marrow-derived pre-B cells that are able to induce leukemia. Consequently, the development of Syk kinase inhibitors could conceivably treat these disorders and so they have became a major focus in the pharmaceutical and biotech industry. In this review, we analyze the structure and role of Syk kinase, the use of small molecules, interacting with ATP-binding site, as inhibitors of kinase activity and finally the potential of using inhibitors of Syk kinase expression to attenuate pathological conditions. Syk kinase inhibition is suggested as a powerful tool for the therapy of different pathologies.Keywords
This publication has 92 references indexed in Scilit:
- Conformational rearrangements upon Syk auto-phosphorylationBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2009
- A Gene Expression Signature Associated with “K-Ras Addiction” Reveals Regulators of EMT and Tumor Cell SurvivalCancer Cell, 2009
- Spleen Tyrosine Kinase Functions as a Tumor Suppressor in Melanoma Cells by Inducing Senescence-like Growth ArrestCancer Research, 2009
- 3D structure of Syk kinase determined by single-particle electron microscopyBiochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 2007
- Autoantibody-mediated demyelination depends on complement activation but not activatory Fc-receptorsProceedings of the National Academy of Sciences, 2006
- Deregulated Syk inhibits differentiation and induces growth factor–independent proliferation of pre–B cellsJournal of Experimental Medicine, 2006
- Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacyNature Biotechnology, 2004
- The Orally Available Spleen Tyrosine Kinase Inhibitor 2-[7-(3,4-Dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide Dihydrochloride (BAY 61-3606) Blocks Antigen-Induced Airway Inflammation in RodentsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Points of control in inflammationNature, 2002
- RNA interferenceNature, 2002